目的 分析沈阳某医院门诊内分泌科甲状腺相关疾病的构成特点,为后续疾病研究和诊疗提供依据。方法 对2018-01-01至2022-12-31沈阳某医院门诊就医的甲状腺疾病患者资料进行分析,以初诊诊断作为疾病分类标准,回顾性分析患者的年龄、性别等。结果 甲状腺疾病初诊前三顺位的病种为甲亢(49.28%)、甲状腺结节(22.81%)和甲减(21.47 %)。甲状腺疾病患者以41～50岁(23.98%)和51～60岁(23.23%)两个年龄段最多,18岁以下(2.31%)和70岁以上(2.75%)年龄段占比最少,男女比例为1∶4.21。甲亢以41～50岁最多(23.63%),31～40岁次之(22.11%)。甲状腺结节以41～50岁最多(29.00%),51～60岁次之(28.08%)。甲减患者成年后逐渐增加,51～60岁最多(26.50%)。结论 甲状腺疾病以中年女性和更年期女性为好发人群,不同病种具有各自的疾病谱特点。
Abstract
Objective To analyze the composition of thyroid related diseases in an outpatient department of endocrinology and to provide evidence for subsequent disease research and diagnosis and treatment. Methods The data of patients with thyroid diseases diagnosed and treated in in a hospital in Shenyang from January 2018 to December 2022 were analyzed. With the initial diagnosis as the thyroid disease classification criteria, the data of patients' age, sex and follow-up were analyzed retrospectively. Results The first three types of thyroid diseases were hyperthyroidism (49.28%), thyroid nodules (22.81%) and hypothyroidism (21.47%). The prevalence of thyroid diseases was high in two age groups of 41-50 (23.98%) and 51-60 (23.23%), but low in age groups below 18(2.31%) and over 70(2.75%). The ratio of male to female was 1∶4.21. Hyperthyroidism was most common in ages 41 to 50(23.63%), followed by 31 to 40(22.11%). The incidence of thyroid nodules was the highest in 41-50 years old (29.00%) and 51-60 years old (28.08%). The incidence of hypothyroidism increased gradually after adulthood, and the highest rate was 26.50% at the age of 51-60. Conclusions Thyroid diseases are common in middle-aged women and menopausal ones, and different thyroid diseases have their own disease characteristics.
关键词
内分泌 /
甲状腺 /
甲状腺功能亢进症 /
甲状腺功能减退症 /
甲状腺结节
Key words
endocrine /
thyroid /
hyperthyroidism /
hypothyroidism /
thyroid nodule
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Fitzgerald S P,Bean N G,Falhammar H,et al.Clinical parameters are more likely to be associated with thyroid hormone levels than with thyrotropin levels:a systematic review and meta-analysis [J].Thyroid,2020,30(12):1695-1709.
[2] Bhakat B,Pal J,Das S,et al.A prospective study to evaluate the possible role of cholecalciferol supplementation on autoimmunity in hashimoto's thyroiditis[J].J Assoc Physicians India,2023,71(1):1.
[3] Lok U,Hatipoghu S,Gulacti U,et al.The role of thyroid and parathyroid metabolism disorders in the etiology of sudden onset dizziness [J].Med Sei Monit,2014,16(20):2689-2694.
[4] Mammen J S,McGready J,Ladenson P W,et al.Unstable thyroid function in older adults is caused by alterations in both thyroid and pituitary physiology and is associated with increased mortality[J].Thyroid,2017,27(11):1370-1377.
[5] 郝志华,王 绵,郝慧瑶,等.河北省城、农村地区成人甲状腺疾病流行病学调查分析[J].中华地方病学杂志,2023,42(4):292-295.
[6] 窦瑜贵,牟啸东,孙 玮,等.2008-2018年兰州市甲状腺疾病患者临床特征分析[J].中华地方病学杂志,2020,39(8):602-605.
[7] 宋述铭,李改琴,张黎峰,等.新疆医科大学附属肿瘤医院2010-2020年恶性肿瘤住院患者流行病学分析[J].实用肿瘤学杂志,2023,37(5):389-394.
[8] 刘婷婷,滕卫平.中国国民碘营养现状与甲状腺疾病[J].中华内科杂志,2017,56(1):62-64.
[9] Ha E J,Baek J H,Na D G.Risk stratification of thyroid nodules on ultrasonography:current status and perspectives [J].Thyroid,2017,27(12):1463-1468.
[10] 郭玉平,张立维,苗 阔,等.成人甲状腺结构及碘营养状况与性别和年龄的相关性研究[J].中国超声医学杂志,2020,36(7):588-591.
[11] 王龙龙,李红强,苌群刚,等.甲状腺癌21980例患者临床病理特征与发病趋势分析[J].中华医学杂志,2020,100(14):1072-1076.
[12] Ha E J,Na D G,Baek J H,et al.US fine-needle aspiration biopsy for thyroid malignancy: diagnostic performance of seven society guidelines applied to 2000 thyroid nodules [J].Radiology,2018,287(3):893-900.
[13] 罗 杰,王学斌,刘智勇,等.碘营养状况对甲状腺癌生物标志物影响的研究进展[J].中华地方病学杂志,2023,42(4):335-339.
[14] 方映雪,徐玉生.某医院6年间甲状腺疾病手术患者流行病学特征及分析[J].中华保健医学杂志,2024, 26(1):116-118.
[15] Leila S,Kenneth D B,Leonard W.Sex differences in differentiated thyroid cancer[J].Thyroid,2022,15(3):224-235.
[16] Alisa D K,Eirini M,Areti P,et al.Thyroid function, sex hormones and sexual function:a mendelian randomization study[J].Eur J Epidemiol,2021,36(3):335-344.
[17] Azizi F,Malboosbaf R.Long-term antithyroid drug treatment:a systematic review and meta-analysis[J]. Thyroid,2017,27(10):1223-1231.
[18] Jawwad M,Ahmed S A,Zaidi S M M,et al.Long-term outcome of treatments for Graves disease in the children and adolescent population[J].Endocrine,2023,81(2):223-230.
[19] Azizi F,Abdi H,Mehran L,et al.Appropriate duration of antithyroid drug treatment as a predictor for relapse of graves' disease: a systematic scoping review[J].Endocrinol Invest,2022,45(6):1139-1150.
PDF(1323 KB)
